A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...

In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

In the ongoing litigation over Apotex's generic version of GlaxoSmithKline's (GSK) antidepressant paroxetine hydrochloride (Paxil), the US Federal Circuit Appeals Court has reversed the previous ...